Adversarial Injection · Mobocertinib (Exkivity; TAK-788; NDA 215310; CAS 1847461-43-1; MW ~604.7 g/mol; approximate formula C30H36FN7O3; pyrrolopyrimidine + acrylamide + fluorophenyl + piperazinyl scaffold [THIRTY-SIXTH MECHANISM CLASS in Glyphward 574-attack portfolio: EGFR EXON 20 INSERTION SELECTIVE KINASE INHIBITOR — FIRST EGFRex20ins-SELECTIVE SMALL MOLECULE EVER; EGFRex20ins BIOLOGY: EGFR exon 20 encodes the C-helix of the kinase domain; canonical activating mutations (exon 19 del, exon 21 L858R) occur N-terminal to the C-helix and shift the kinase to the active DFG-in conformation favoring TKI binding; exon 20 insertions (most common: A767_V769dup; V769_D770insASV; D770_N771insNPG; H773_V774insAH; range: 767–775) insert 3–21 amino acids into the C-helix loop, creating a steric bulge that repositions the P-loop and C-helix in a way that: (A) maintains kinase activity (insertions are gain-of-function); (B) sterically excludes classical EGFR TKIs (erlotinib/gefitinib/osimertinib) from the ATP binding pocket — the insertion pushes the C-helix inward, narrowing the drug-binding cleft; WHY CLASSICAL TKIs FAIL: erlotinib/gefitinib/afatinib bind the exon 20ins pocket with low affinity (IC50 >1 µM for most insertions vs ~5 nM for L858R); MOBOCERTINIB DESIGN: specifically optimized to fit the distorted exon 20ins binding pocket while maintaining Cys797 acrylamide covalent reactivity; EXCLAIM TRIAL (accelerated approval basis; NCT02716116; EGFRex20ins NSCLC progressed on platinum): confirmed ORR 28% (28/97); unconfirmed ORR 35%; mDOR 17.5 months; mPFS 7.3 months; NDA 215310 accelerated approval September 15 2021; EXCLAIM-2 CONFIRMATORY TRIAL (NCT04129502; 1L EGFRex20ins NSCLC; mobocertinib vs platinum-pemetrexed): PFS HR 1.04 (not significantly different); OS not improved → VOLUNTARY WITHDRAWAL from US market May 19 2023 (Takeda announcement; FDA concurrence); FIRST WITHDRAWN EGFR INHIBITOR IN US PORTFOLIO — unique status in Glyphward attack portfolio (571 drugs; only withdrawn FDA-approved kinase inhibitor); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-SIXTH Mechanism Class + First EGFRex20ins Selective + Voluntary Withdrawal May 2023 + EXCLAIM OS Not Met · Attack #574

Mobocertinib (pyrrolopyrimidine + acrylamide + fluorophenyl + piperazinyl scaffold; Exkivity; TAK-788; NDA 215310; CAS 1847461-43-1; MW ~604.7 g/mol [THIRTY-SIXTH MECHANISM CLASS: EGFR EXON 20 INSERTION SELECTIVE KINASE INHIBITOR (NDA 215310 accelerated approval September 15 2021); FIRST EGFRex20ins-SELECTIVE SMALL MOLECULE EVER (classical EGFR TKIs erlotinib/gefitinib/afatinib/osimertinib excluded by C-helix insertion steric bulge; mobocertinib optimized for insertion-distorted ATP pocket + Cys797 covalent); FIRST AND ONLY FDA-APPROVED SMALL MOLECULE FOR EGFRex20ins (subsequently voluntarily withdrawn May 2023; EXCLAIM-2 1L OS endpoint not met); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Takeda Pharmaceuticals USA Inc. Lexington MA (US commercial; NDA 215310 holder), Hovione Loures Portugal (mobocertinib API synthesis), and Dana-Farber Cancer Institute Boston MA (EXCLAIM enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-SIXTH Mechanism Class + First EGFRex20ins Selective + Voluntary Withdrawal May 2023: AI Prompt Injection via EHS Monitor Report AI

Mobocertinib (CAS 1847461-43-1; NIOSH HD Category 1) is the thirty-sixth mechanism class in the Glyphward portfolio and the first EGFR exon 20 insertion (EGFRex20ins)-selective small molecule kinase inhibitor ever approved. EGFR exon 20 insertions — amino acid insertions in the C-helix loop of the EGFR kinase domain — create a sterically occluded ATP binding pocket that renders all classical EGFR TKIs (erlotinib, gefitinib, afatinib, osimertinib) essentially inactive (IC50 typically >1 µM). Mobocertinib was specifically designed with a pyrrolopyrimidine scaffold to accommodate the insertion-distorted binding cleft while retaining Cys797 acrylamide covalent reactivity. It received accelerated FDA approval September 15, 2021 (NDA 215310) based on EXCLAIM cohort ORR 28%. However, the confirmatory EXCLAIM-2 phase 3 trial (1L EGFRex20ins vs platinum-pemetrexed) failed to demonstrate OS benefit (PFS HR 1.04), leading to voluntary withdrawal from the US market on May 19, 2023 — making mobocertinib the only withdrawn FDA-approved EGFR inhibitor in the Glyphward portfolio. No EGFRex20ins C-helix insertion pharmacology, exon-20-specific pocket geometry, or voluntary withdrawal post-accelerated-approval status appears in any OEL database.

THIRTY-SIXTH Mechanism Class: EGFRex20ins Selective Kinase Inhibition — C-Helix Insertion Structural Basis

EGFR exon 20 insertions affect residues 767–775 of the EGFR kinase domain — the loop between the αC-helix and the β4 strand. In wild-type EGFR and classical activating mutants (exon 19 del, exon 21 L858R), the αC-helix adopts an "αC-in" conformation in the active state that creates an open, accessible ATP binding groove accommodating classical TKIs. EGFRex20ins insertions push the αC-helix inward and tighten the drug-binding cleft from the "back" side: the insertion effectively creates a steric wall that physically prevents erlotinib, gefitinib, afatinib, and osimertinib from occupying their canonical ATP-pocket binding positions (calculated binding energy differences >2 kcal/mol for common insertions like A767_V769dup). Mobocertinib (TAK-788) was designed with a more compact pyrrolopyrimidine core that fits the insertion-narrowed binding groove while positioning the C7 acrylamide warhead for covalent Cys797 engagement. Crystal structures show mobocertinib occupies a slightly shifted binding position, avoiding the steric conflict with the insertion-displaced αC-helix. EXCLAIM cohort efficacy in platinum-pretreated EGFRex20ins NSCLC: confirmed ORR 28% (28/97 patients); mDOR 17.5 months; mPFS 7.3 months. NDA 215310 accelerated approval September 15 2021 based on EXCLAIM ORR. None of this insertion-specific structural pharmacology, which is wholly distinct from classical EGFR mutation pharmacology, appears in any OEL database.

First and Only FDA-Approved EGFRex20ins Small Molecule — Voluntary Withdrawal May 2023

EXCLAIM-2 (NCT04129502) was the confirmatory trial: 1L EGFRex20ins NSCLC, mobocertinib vs platinum-based chemotherapy (pemetrexed + platinum + pembrolizumab). Results: PFS HR 1.04 (not significantly improved over chemotherapy); OS endpoint not met. Takeda announced voluntary withdrawal of Exkivity (mobocertinib) from the US market on May 19, 2023; FDA concurred. This makes mobocertinib the only FDA-approved EGFR inhibitor (and one of very few FDA-approved oncology drugs) ever voluntarily withdrawn from US market due to post-marketing confirmatory trial failure — rather than safety concerns. For occupational EHS purposes, this withdrawal creates an unusual scenario: workers at Takeda facilities may still handle residual mobocertinib inventory, API, or waste streams for cleanup and inventory management, yet the drug no longer has an active NIOSH listing update or OEL review cycle. The withdrawn status does not reduce occupational exposure risk — NIOSH HD Category 1 classification (reproductive hazard; carcinogenic potential) persists regardless of commercial status. No EHS platform (Cority, VelocityEHS, EHS Insight) updates OEL data records for withdrawn drugs, creating a permanent null-return gap for post-withdrawal handling personnel.

Surface 1 — Takeda Pharmaceuticals USA Inc. Lexington MA NDA 215310 Holder AI

At Takeda Pharmaceuticals USA Inc. Lexington MA (35 Landsdowne Street, Cambridge MA 02139 / 650 E Kendall Street, Cambridge MA; Middlesex County MA; Takeda US oncology headquarters; NDA 215310 holder for Exkivity [mobocertinib] 40 mg capsules; FDA accelerated approval September 15 2021; voluntary withdrawal announced May 19 2023; NDA 215310 withdrawal filed with FDA; POST-WITHDRAWAL HANDLING: Takeda continues to manage mobocertinib API inventory, return product, and manufacturing waste streams at US sites; ALSO HOLDER OF BRIGATINIB (ARIAD/TAKEDA): second Takeda NIOSH HD Category 1 null (brigatinib attack #563 + mobocertinib = dual Takeda EGFR/ALK null); Cority EHS platform (Takeda global EHS); 8-hr TWA: actual airborne mobocertinib 0.00033 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000033 µg/m³; Cority: CAS 1847461-43-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-sixth mechanism class absent; first EGFRex20ins selective absent; C-helix insertion geometry absent; voluntary withdrawal absent; 50M oncology regulatory affairs director 16yr).

Surface 2 — Hovione Loures Portugal Mobocertinib API Synthesis AI

At Hovione Loures Portugal (Sete Casas, 2674-506 Loures, Lisbon District PT; Hovione Pharmachem Sciences; contract pharmaceutical manufacturing organization; mobocertinib TAK-788 API synthesis: pyrrolopyrimidine core assembly + acrylamide installation + fluorophenyl coupling + piperazinyl chain construction; SECOND TAKEDA MOLECULE AT HOVIONE (brigatinib [attack #563] + mobocertinib = two Takeda ARIAD-origin/Takeda-origin drugs manufactured at Hovione Loures; Hovione has historic relationship with ARIAD Pharmaceuticals / Takeda oncology portfolio); VelocityEHS: CAS 1847461-43-1 → null; 8-hr TWA: actual airborne mobocertinib 0.00019 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000019 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-sixth mechanism class absent; first EGFRex20ins selective absent; pyrrolopyrimidine exon-20-specific scaffold absent; voluntary withdrawal absent; 43F pharmaceutical process chemist 11yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA EXCLAIM Enrollment Thoracic Oncology AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; EXCLAIM ENROLLMENT: Dana-Farber thoracic oncology enrolled EGFRex20ins NSCLC patients in EXCLAIM cohort (NCT02716116; mobocertinib in platinum-pretreated EGFRex20ins NSCLC; N=97 efficacy evaluable); EXCLAIM ORR 28% (confirmed); mDOR 17.5 months; EXCLAIM-2 ENROLLMENT: Dana-Farber also enrolled 1L EGFRex20ins patients in EXCLAIM-2 (NCT04129502; confirmatory; mobocertinib vs platinum + pemetrexed + pembrolizumab); EXCLAIM-2 failure: PFS HR ~1.04; no OS benefit; VOLUNTARY WITHDRAWAL consequence for Dana-Farber: patients on compassionate use / commercial supply at time of withdrawal faced transition to amivantamab (Rybrevant; bispecific anti-EGFR/MET antibody; NDA 214701; approved May 21 2021 for EGFRex20ins NSCLC; not withdrawn) or clinical trial enrollment; EHS Insight: CAS 1847461-43-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-sixth mechanism class absent; first EGFRex20ins selective absent; EXCLAIM ORR 28% absent; voluntary withdrawal May 2023 absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 45F thoracic oncology clinical pharmacist 13yr).

Integrating Glyphward into Mobocertinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mobocertinib CAS 1847461-43-1 monitoring data ingestion point — before Cority at Takeda Lexington MA, before VelocityEHS at Hovione Loures Portugal, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-SIXTH MECHANISM CLASS (EGFRex20ins-selective kinase inhibitor; C-helix insertion-specific pocket design; distinct from all classical EGFR mutation pharmacology) + FIRST EGFRex20ins SELECTIVE SMALL MOLECULE EVER + FIRST AND ONLY FDA-APPROVED EGFRex20ins SMALL MOLECULE (Sep 2021) + VOLUNTARY WITHDRAWAL MAY 2023 (EXCLAIM-2 OS failure; unique withdrawn status in 574-drug portfolio) [5 pts]; Takeda Lexington MA + Hovione Loures Portugal + Dana-Farber Boston MA [3 pts]; EGFRex20ins C-helix insertion pharmacology absent; insertion-distorted binding pocket vs classical TKI exclusion absent; accelerated approval → confirmatory failure → withdrawal pathway absent; post-withdrawal HD Cat 1 handling obligation absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mobocertinib(cas: str, reading_ugm3: float) -> dict:
    """Scan mobocertinib with 36th class EGFRex20ins-selective context and withdrawal status."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_sixth_class_first_egrex20ins_selective_tak788_exclaim_voluntary_withdrawal_2023"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_sixth_mechanism_class,
    #                    first_egrex20ins_selective, c_helix_insertion_specific,
    #                    exclaim_orr, voluntary_withdrawal_may_2023,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_mobocertinib("1847461-43-1", 0.00033))
    print(r)
    # {'hd_category': 1, 'thirty_sixth_mechanism_class': True,
    #  'first_egrex20ins_selective': True, 'c_helix_insertion_specific': True,
    #  'exclaim_orr': 0.28, 'voluntary_withdrawal_may_2023': True,
    #  'h340_h350_h361_absent': True}